Literature DB >> 7954327

Germline and somatic abnormalities of chromosome 7 in Wilms' tumor.

H P Wilmore1, G F White, R T Howell, K W Brown.   

Abstract

Although a gene (WT1) located at chromosome 11p13 is implicated in the development of Wilms' tumor (WT), there is evidence that genes on other chromosomes are also involved. A WT patient presented with a constitutional balanced translocation between chromosomes 1 and 7, t(1;7)(q42;p15), the breakpoints of which could represent a WT predisposition gene in this patient. Cytogenetic analysis of the tumor from this patient revealed an acquired abnormality of the other chromosome 7, resulting in an isochromosome of the long arm and a 46,XY,t(1;7)(q42;p15)c,i(7)(q10) karyotype. The regions of the translocation breakpoints were investigated in a series of 24 WTs using Southern blot analysis. This confirmed the monosomy of 7p and trisomy of 7q in the tumor of the translocation patient, and in addition a loss of chromosome 7p alleles was identified in a WT of a bilaterally affected patient. In addition, two WTs were shown to have an extra copy of chromosome 7 alleles. Multiple copies of chromosome 1q alleles, probably resulting from secondary changes, were observed in two WTs, one of which was also associated with a trisomy of chromosome 7. These results indicate that 7p may contain a tumor suppressor gene involved in WT development, and that duplications of 7q also may play a role in WT development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954327     DOI: 10.1016/0165-4608(94)90221-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumour.

Authors:  P R Hoban; R L Cowen; E L Mitchell; D G Evans; M Kelly; P J Howard; J Heighway
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

Review 2.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

3.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

4.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.

Authors:  S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

5.  Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study.

Authors:  A K Charles; S Mall; J Watson; P J Berry
Journal:  Mol Pathol       Date:  1997-06

Review 6.  Wilms tumour: diagnosis and treatment.

Authors:  M J Coppes; J E Wolff; M L Ritchey
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

7.  Bilateral burkitt lymphoma of the ovaries: a report of a case in a child with williams syndrome.

Authors:  Grace Ifeyinwa Onimoe; Samir Kahwash; Amanda Termuhlen; Thomas G Gross; Elizabeth Varga; Melissa J Rose
Journal:  Case Rep Med       Date:  2011-05-26

8.  Loss of heterozygosity at 7p in Wilms' tumour development.

Authors:  R M Powlesland; A K Charles; K T Malik; P A Reynolds; S Pires; M Boavida; K W Brown
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Authors:  Kylie M Drake; E Cristy Ruteshouser; Rachael Natrajan; Phyllis Harbor; Jenny Wegert; Manfred Gessler; Kathy Pritchard-Jones; Paul Grundy; Jeffrey Dome; Vicki Huff; Chris Jones; Micheala A Aldred
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 10.  Genetic Predisposition to Solid Pediatric Cancers.

Authors:  Mario Capasso; Annalaura Montella; Matilde Tirelli; Teresa Maiorino; Sueva Cantalupo; Achille Iolascon
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.